“Selecting the Optimal Treatment Line for CDK4 6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Breast Cancer”. 2026. Voprosy Onkologii 72 (3): OF-2455. https://doi.org/10.37469/0507-3758-2026-72-3-OF-2455.